Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences in June
29 mai 2019 08h05 HE
|
Corbus Pharmaceuticals Holdings, Inc.
Norwood, MA, May 29, 2019 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company focused on treating...
Corbus Pharmaceuticals Announces Presentation of Six Abstracts at EULAR 2019 Annual Meeting
28 mai 2019 08h05 HE
|
Corbus Pharmaceuticals Holdings, Inc.
New data from ongoing Phase 2 open-label extension of lenabasum in systemic sclerosis and open-label extension data in dermatomyositis studies to be presentedPresentation includes data from some...
Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences in May
15 mai 2019 08h05 HE
|
Corbus Pharmaceuticals Holdings, Inc.
Norwood, MA, May 15, 2019 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company focused on treating...
Corbus Pharmaceuticals Reports 2019 First Quarter Financial Results and Provides Clinical Updates
09 mai 2019 07h00 HE
|
Corbus Pharmaceuticals Holdings, Inc.
Continued progress made in four ongoing clinical studies as lenabasum advances towards 2020 data readouts in lead indications systemic sclerosis and cystic fibrosis Second clinical candidate...
Corbus Pharmaceuticals Completes Enrollment of RESOLVE-1 Phase 3 Study of Lenabasum for Treatment of Systemic Sclerosis
02 mai 2019 08h05 HE
|
Corbus Pharmaceuticals Holdings, Inc.
Company anticipates topline results of RESOLVE-1 study in the summer of 2020Systemic sclerosis (SSc) is a chronic, rare systemic autoimmune disease affecting approximately 200,000 people in the U.S.,...
Corbus Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter 2019 Operational and Financial Results on May 9, 2019
01 mai 2019 08h05 HE
|
Corbus Pharmaceuticals Holdings, Inc.
Norwood, MA, May 01, 2019 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company focused on treating...
Corbus Pharmaceuticals Announces Change of Primary Endpoint in Ongoing RESOLVE-1 Phase 3 Study in Systemic Sclerosis in U.S. to ACR CRISS from mRSS Following Meeting with FDA
18 avr. 2019 08h05 HE
|
Corbus Pharmaceuticals Holdings, Inc.
Phase 3 primary endpoint will now be aligned with that of previous Phase 2 studyACR CRISS is a composite index (composed of multiple outcomes including mRSS) and was secondary endpoint in current...
Corbus Pharmaceuticals Appoints Rachelle Jacques to Board of Directors
08 avr. 2019 08h05 HE
|
Corbus Pharmaceuticals Holdings, Inc.
Appointment brings global commercialization and marketing experience for rare diseases to the Board of Directors Appointment aligns with Company’s vision to become the leader in the treatment of...
Corbus Pharmaceuticals Provides Management Team Updates
28 mars 2019 08h05 HE
|
Corbus Pharmaceuticals Holdings, Inc.
Mark Tepper, Ph.D., transitions to role of external Senior Scientific Advisor Robert Discordia, Ph.D., role expanded to lead Chemistry, Manufacturing and Controls operationsSergei Atamas, M.D.,...
Corbus Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Clinical Updates
12 mars 2019 07h00 HE
|
Corbus Pharmaceuticals Holdings, Inc.
●Pipeline of rationally-designed synthetic cannabinoids position Corbus to become the leader in treating inflammatory and fibrotic diseases by targeting the endocannabinoid system (ECS)...